Form 4: Alaunos Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Dale Curtis Hogue Jr., Chief Executive Officer of Alaunos Therapeutics, acquired 3,000 employee stock options on March 29, 2025.
Summary
- On March 29, 2025, Dale Curtis Hogue Jr., the Chief Executive Officer of Alaunos Therapeutics, acquired 3,000 employee stock options.
- The options have an exercise price of $1.46.
- One-sixth of the shares underlying the option vest in equal monthly installments measured from March 29, 2025, with the first vesting occurring on April 29, 2025, subject to continued service.
- The options expire on March 28, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to an executive. The acquisition of options by the CEO could be interpreted as a slightly positive signal, but it's a routine event.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the CEO's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- Shareholders may view the CEO's stock option acquisition as a sign of confidence in the company's future prospects.
- Employees may see this as a positive indicator of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/29/2025 | Date of the transaction: Dale Curtis Hogue Jr. acquired 3,000 employee stock options. |
| 03/29/2025 | Vesting start date: One-sixth of the shares underlying the option vest in equal monthly installments measured from March 29, 2025. |
| 04/29/2025 | First vesting date: The first vesting occurs on April 29, 2025. |
| 03/28/2035 | Expiration date: The options expire on March 28, 2035. |
| 03/31/2025 | Date of signature on the Form 4 filing. |
Keywords
Alaunos Therapeutics, stock options, Form 4, executive compensation, TCRT, insider trading, Hogue Dale Curtis Jr., CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.